PHCCC is a potent PAM (positive allosteric modulator) of mGluR4 and a Group I metabotropic glutamate receptor antagonist with IC₅₀ of ~ 3 μM. It is 67 times more potent than (S)-4-carboxyphenylglycine and potentiates L-AP4-mediated inhibition of striatopallidal synaptic transmission in vitro. Displays antiParkinsonian effects in rats in vivo. PHCCC exhibits proconvulsant action in three models of epileptic seizures in immature rats. PHCCC reduces proliferation and promotes differentiation of cerebellar granule cell neuroprecursors. PHCCC showed neuroprotection against betaAP- and NMDA-toxicity in mixed cultures of mouse cortical neurons. This neuroprotection was additive to that induced by the highly efficacious mGluR1 antagonist CPCCOEt and was blocked by MSOP, a group-III mGluR antagonist. Our data provide evidence for a novel pharmacological site on mGluR4, which may be used as a target-site for therapeutics.

纯度：≥98%

CAS：179068-02-1